Status:
COMPLETED
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patie...
Eligibility Criteria
Inclusion
- Diabetes mellitus
- Use NovoPen®, NovoPen® 1.5, NovoPen® 3, NovoLet® 1.5 or NovoLet® 3 for at least 3 months
- Body mass index (BMI) for normal weight between 19-25 kg/m2
- Body mass index (BMI) for obese between 25-33 kg/m2
Exclusion
- Pregnancy or plans thereof
- Local reactions on injection sites
- Acute, severe infection diseases
- Coagulation disorders
Key Trial Info
Start Date :
April 9 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 1997
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00871416
Start Date
April 9 1997
End Date
July 18 1997
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Aarhus, Denmark, 8000